We are international
Donate
TEXT SIZE   
back

IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
04.20.10

IMWG GUIDELINES FOR THE PREVENTION OF THALIDOMIDE- AND LENALIDOMIDE-ASSOCIATED THROMBOSIS IN MYELOMA1

The risk of VTE in cancer patients is greater than 7%; those with myeloma have the highest risk of thrombosis.2 The oral immunomodulatory drugs, thalidomide and lenalidomide, further increase that risk. The following guidelines from the International Myeloma Working Group recommend a prophylaxis strategy based upon a risk assessment model. The recommendations have been made in the absence of clear data from randomized studies, and are therefore based on common sense and on data extrapolated from many studies not specifically designed to answer these questions. Treatment decisions must be based on the type of therapy and the patient’s individual risk factors.

Risk factors for venous thromboembolism (VTE) in myeloma patients

  • Individual
    • Obesity (defined as body mass index > 30kg/m2)
    • Previous venous thromboembolism
    • Central venous catheter or pacemaker
    • Associated disease
      • Cardiac disease
      • Chronic renal disease
      • Diabetes
      • Acute infection
      • Immobilization
    • Surgery
      • General surgery
      • Any anesthesia
      • Trauma
    • Medications
      • Erythropoietin
    • Blood clotting disorders
  • Myeloma-related risk factors
    • Diagnosis per se
    • Hyperviscosity
  • Myeloma therapy (all are to be considered high-risk factors)
    • High-dose dexamethasone
    • Doxorubicin
    • Multiagent chemotherapy

Recommendations for VTE prophylaxis in myeloma patients based on risk factors
Both individual and myeloma-related risks of VTE should be taken into account in determining the type of thromboprophylaxis.

  • If no risk factor, or any one risk factor is present, aspirin 81-325 mg once daily is recommended.
  • If two or more risk factors are present, LMWH (equivalent of enoxaparin 40 mg once daily) or full-dose warfarin, international normalized ratio (INR) 2-3, is recommended.
  • If any myeloma therapy-related risk factor is present, then LMWH (equivalent of 40 mg enoxaparin once daily) or full-dose warfarin (target INR 2-3) is recommended.

Recommendations for VTE prophylaxis in myeloma patients based on type of therapy

  • Thalidomide
    • Patients receiving single-agent thalidomide: anticoagulation therapy not recommended
    • Newly diagnosed patients receiving thal/dex: full-dose warfarin
    • Newly diagnosed patients treated with combinations that include melphalan (i.e. MPT): low-molecular-weight heparin (LMWH)
    • Newly diagnosed patients treated with thalidomide + multiagent chemotherapies: LMWH, low-fixed-dose warfarin, and full-dose aspirin not effective
    • Newly diagnosed patients treated with thal + doxorubicin when the regimen contains bortezomib: LMWH effective
    • Relapsed patients: anticoagulant prophylaxis suggested only in those with a high risk of VTE
  • Lenalidomide
    • Patients receiving single-agent lenalidomide: anticoagulation therapy not recommended
    • Patients receiving lenalidomide plus low-dose dexamethasone,  melphalan, or doxorubicin: aspirin recommended (if no or one risk factor present)
    • Patients receiving high-dose dexamethasone: LMWH or full-dose warfarin recommended

Diagnosis and Management of VTE

  • Diagnosis
    • Compression ultrasonography the diagnostic test of choice for suspect VTE
    • Computed tomography (CT) pulmonary angiography most widely used diagnostic test for pulmonary embolism (PE)
    • Magnetic resonance pulmonary angiography may be used as an alternative to CT pulmonary angiography in patients who have a contraindication to iodinized contrast media
  • Treatment
    • Patients should be instructed to inform the physician if any of the following symptoms occur:
      • Redness of the skin
      • Pain in the extremities or chest
      • Shortness of breath
      • Rapid heartbeat
    • Appropriate initial therapy for patients with DVT is LMWH
      • Discontinue therapy with thalidomide or lenalidomide and resume when full anticoagulation has been established
      • If risk of thrombocytopenia is low, oral anticoagulation should be started on the first day of treatment
      • Heparin should be given for a minimum of 5 days and not stopped until a patient’s INR is from 2.0-3.0 for 2 consecutive days
      • Extended therapy with LMWH should be considered, balancing its advantages with disadvantages such as cost, the need for daily injections, and the risk of osteoporosis
Long-term therapy with LMWH or with warfarin should be continued for the total duration of thalidomide or lenalidomide therapy

1A Palumbo et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2008); 22: 414-423.

2JW Blom et al. Malignancy, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005); 293: 715-722.
 related videos
 related articles
IMWG consensus state...
IMWG Guidelines for ...
IMWG Guidelines for ...
IMWG Guidelines for ...
International Myelom...
International Myelom...
A Practical Guide to...
ASCO 2010: Lenalidom...
ASCO 2010: Phase I s...
ASCO 2010: Phase Ib ...
Oncology Nurses Take...
ASCO 2010: Total the...
Genetic association ...
Genetic Variations A...
Advocacy Update - Se...
Advocacy Update - Se...
ASCO 2010: A phase I...
ASCO 2010: Bone mark...
ASCO 2010: Elotuzuma...
ASCO 2010: Mechanism...
ASCO 2010: Modified ...
ASCO 2010: Multiple ...
ASCO 2010: Neurotoxi...
ASCO 2010: Results o...
ASCO 2010: Stromal e...
Clinically relevant ...
Common Symptoms Of M...
Confirmation of the ...
Developing a SNP Cla...
Eliminating the comp...
ESAs not the culprit...
Genetic Associations...
Genetic Associations...
Genetic polymorphism...
Genomic variation in...
IMWG Criteria for th...
Long-Term Follow-Up ...
Long-Term Follow-Up ...
New Approaches to Tr...
Osteonecrosis of the...
RT-PCR Amplicons in ...
Survival and Years o...
Use of Bisphosphonat...

Statement on the pas...
Inaugural Summit of ...
International Myelom...

ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
What is multiple myeloma?
Dr. Morie Gertz of the Mayo Clinic in Rochester, MN.
IMWG consensus statement on the role of vertebral augmentation in multiple myeloma
IMWG Guidelines for Facilities and Services for the Management of Myeloma Patients
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
IMWG Guidelines for the Use of Bisphosphonates in Myeloma
International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma
International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma1
A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable Proceedings
ASCO 2010: Lenalidomide maintenance after transplantation for myeloma.
ASCO 2010: Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
Advocacy Update - September 1, 2009
Advocacy Update - September 15, 2009
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
ASCO 2010: Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.
ASCO 2010: Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.
ASCO 2010: Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
ASCO 2010: Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.
Clinically relevant end points and new drug approvals for myeloma
Common Symptoms Of Multiple Myeloma
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Eliminating the complete response penalty from myeloma response criteria
ESAs not the culprit: More studies required
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Genetic polymorphisms of EPHX1, Gsk3 beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
IMWG Criteria for the Diagnosis of Myeloma and Guidelines for the Diagnostic Work-Up of Myeloma
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
Osteonecrosis of the Jaw and Biphosphonates
RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients
Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
Use of Bisphosphonates in Multiple Myeloma: IMGW Response to Mayo Clinic Consensus Statement
WHAT IS MULTIPLE MYELOMA
Statement on the passing of Senator Kennedy
Inaugural Summit of the International Myeloma Working Group Lays the Groundwork for a Course Toward a Cure.
International Myeloma Working Group at ASH 2009